(19)
(11) EP 1 603 949 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.03.2010 Bulletin 2010/10

(45) Mention of the grant of the patent:
27.01.2010 Bulletin 2010/04

(21) Application number: 04720349.2

(22) Date of filing: 12.03.2004
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 37/00(2006.01)
 A61K 39/395(2006.01)
A61P 37/06(2006.01)
(86) International application number:
PCT/US2004/007444
(87) International publication number:
WO 2004/083249 (30.09.2004 Gazette 2004/40)

(54)

ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR

ANTIKÖRPER GEGEN IL21-REZEPTOR UND DEREN VERWENDUNG

ANTICORPS DIRIGES CONTRE LE RECEPTEUR HUMAIN DE L'IL-21 ET UTILISATIONS CORRESPONDANTES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 14.03.2003 US 454336 P

(43) Date of publication of application:
14.12.2005 Bulletin 2005/50

(60) Divisional application:
09178337.3

(73) Proprietors:
  • Wyeth
    Madison, NJ 07940 (US)
  • MedImmune Limited
    Cambridge CB1 6GH (GB)

(72) Inventors:
  • YOUNG, Deborah, A.
    Melrose, MA 02176 (US)
  • WHITTERS, Matthew, J.
    Hudson, MA 01749 (US)
  • VALGE-ARCHER, Viia
    Cambridge CB1 6BE (GB)
  • COLLINS, Mary
    Natick, MA 01760 (US)
  • WILLIAMS, Andrew James
    Herts, SG8 7TG (GB)
  • WITEK, Joanne
    Acton, MA 01720 (US)

(74) Representative: Rupp, Christian 
Mitscherlich & Partner Patent- und Rechtsanwälte Postfach 33 06 09
80066 München
80066 München (DE)


(56) References cited: : 
WO-A-01/77171
WO-A-03/028630
US-A1- 2003 148 447
 WO-A-01/85792
US-A1- 2002 128 446
   
  • COLLINS MARY ET AL: "IL-21 and IL-21 receptor: A new cytokine pathway modulates innate and adaptive immunity." IMMUNOLOGIC RESEARCH, vol. 28, no. 2, 2003, pages 131-140, XP009036147 ISSN: 0257-277X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).